Call Us Today
Call Us Today
Steve Kherkher - August 24, 2026
A federal multidistrict litigation (MDL) is underway involving allegations that certain GLP-1 medications may be associated with non-arteritic anterior ischemic optic neuropathy (NAION), a serious condition that can cause sudden vision loss. The litigation includes claims involving popular weight loss medications like Ozempic, Wegovy, Mounjaro, and Zepbound.
If you or a loved one experienced sudden or significant vision loss after taking a GLP-1 medication, understanding the current medical research and legal status may help you understand your legal rights and potential options. The defective drug attorneys at Kherkher Garcia want consumers to be informed. We have prepared an update on the status of GLP-1 NAION lawsuits. If you have any questions, please do not hesitate to reach out to our team.
GLP-1 NAION lawsuits involve claims that certain manufacturers failed to adequately warn patients and healthcare providers about a risk of NAION associated with GLP-1 receptor agonist medications.
The federal cases have been united as MDL No. 3163, In re: GLP-1 RAs Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation, in the U.S. District Court for the Eastern District of Pennsylvania before Judge Karen Spencer Marston. The Judicial Panel on Multidistrict Litigation (JPML) established the MDL after finding common factual questions involving the drugs’ development, testing, labeling, and alleged capacity to cause NAION.
The GLP-1 NAION litigation continues to move through coordinated federal proceedings. The court has established procedures for direct filing, discovery, preservation of evidence, and other aspects of the lawsuits.
In July, 2026, Judge Marston issued Case Management Order No. 12, addressing early discovery concerning issues that could affect multiple cases. The order confirms that the litigation involves personal injury claims alleging that GLP-1 medications caused NAION. The order reflects the court’s ongoing effort to identify and address common issues across the cases before individual claims move further through litigation.
Also in June, 2026, the court held a Science Day concerning the medical and scientific issues underlying GLP-1 NAION lawsuits. The court’s previous order limited the presentation to topics including the diseases treated by GLP-1 medications, the drugs’ labeling and regulatory history relevant to NAION, the eye and NAION, and scientific literature concerning the potential relationship between GLP-1 medications and the alleged injury. Science Days are educational proceedings that can help the court understand complicated scientific questions.
The JPML united the federal cases in December 2025. At the time, the Panel identified 21 actions pending in three federal districts and nine related actions.
The current federal NAION MDL involves claims concerning several GLP-1 receptor agonists and GLP-1/GIP medications. Court documents identify:
The more notable manufacturers in the lawsuits include Novo Nordisk and Eli Lilly.
Non-arteritic anterior ischemic optic neuropathy, or NAION, is a condition involving reduced blood flow to the optic nerve. This can result in sudden vision loss. The optic nerve carries visual information from the eye to the brain. When damage occurs to the optic nerve, vision may be permanently affected. NAION is sometimes referred to as “eye stroke” because it involves a disruption of blood supply to the optic nerve.
According to Mass General Brigham Eye and Ear researchers, NAION can cause painless vision loss that may progress over several days before stabilizing. There are currently no effective treatments that reliably restore the lost vision.
NAION often causes sudden, painless vision loss in one eye. People may notice:
These symptoms can have other causes, so it is important to get prompt medical evaluation.
Research has identified a possible association between drugs containing semaglutide and NAION, but the scientific question remains under investigation.
A 2024 study led by researchers at Mass Eye and Ear examined patients who had been prescribed semaglutide, the active ingredient in Ozempic and Wegovy. Researchers found that patients with diabetes who had been prescribed semaglutide were more than four times as likely to be diagnosed with NAION. Patients who were significantly overweight were more than seven times as likely to receive the diagnosis compared with patients who had not been prescribed semaglutide.
The researchers emphasized that the findings identified an association and warranted additional study rather than establishing that semaglutide directly causes NAION. Subsequent research has also examined the potential relationship between semaglutide and NAION, adding to the scientific questions being considered in the current litigation.
GLP-1 NAION lawsuits claim that manufacturers failed to adequately warn patients and healthcare providers about the risk of NAION. They also allege design defects and breach of warranties. A product-liability case like this one may require evidence addressing issues such as:
The evidence and legal requirements for any of these claims will vary depending on the individual case. The NAION lawsuits are separate from other litigation related to Ozempic and gastrointestinal illnesses.
Permanent vision loss can affect employment, independence, mobility, relationships, and quality of life. Depending on the severity of the impairment, a person may require additional medical care, vision rehabilitation, assistive technology, transportation assistance, and modifications to their home. Some people may also experience difficulty returning to the same occupation or maintaining the same level of income.
The impact of vision loss is highly individual, which is why the circumstances of each potential claim requires a separate evaluation.
A sudden loss of vision can change nearly every aspect of a person’s life. When that loss occurs after taking a prescription medication, determining what happened requires careful review. At Kherkher Garcia, we represent individuals in complex pharmaceutical and product liability litigation. Our attorneys work with medical and scientific experts when appropriate to investigate serious injuries and evaluate potential claims against manufacturers.
We understand that pharmaceutical litigation can involve complicated medical evidence and evolving scientific questions. Our goal is to help clients understand the legal process while pursuing the claims supported by the facts and applicable law.
If you or a loved one experienced sudden vision loss or were diagnosed with NAION after using a GLP-1 medication, contact Kherkher Garcia for a free consultation to discuss your injuries, legal rights, and potential legal options. Call 713-333-1030, or submit our website contact form to get started.
The MDL includes claims involving Ozempic, Wegovy, Rybelsus, Saxenda, Trulicity, Mounjaro, and Zepbound.
NAION is a condition involving damage to the optic nerve associated with reduced blood flow, and it can cause sudden vision loss. It is sometimes called an “eye stroke.”
No. Taking a GLP-1 medication does not mean that a person will develop NAION. Researchers are investigating a possible association between some GLP-1 medications and an increased risk or occurrence.
Eligibility depends on the specific medication, diagnosis, timing, medical history, applicable law, and other facts. An attorney can evaluate the circumstances of an individual case.
Image by wirestock on Magnific
This page has been written, edited, and reviewed by a team of legal writers following our comprehensive editorial guidelines. This page was approved by attorneys Steve Kherkher and Jesus Garcia Jr., who have more than 50 years of combined legal experience championing the rights of those who have experienced catastrophic injury due to negligence.
Connect with a Kherkher Garcia trial lawyer today to pursue maximum compensation for your injury.
